[Comment] Ultra-long-acting biological therapy for chronic rhinosinusitis with nasal polyps

Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a common and particularly severe subset of sinonasal inflammatory disease that is characterised by benign outgrowths of the inflamed mucosa. The management framework of CRSwNP substantially shifted with the introduction of biological agents.1–3 These therapies, targeting the Th2 cell cytokine pathways, drove reductions in both systemic steroid use and surgical interventions. Biological drugs were able to provide significant and sustained control of symptoms without the need for revision sinus surgery.